Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic Takes Aim At Implantable Device Infections with TYRX Buy

This article was originally published in The Gray Sheet

Executive Summary

The $160 million cash acquisition fits with the firm’s efforts to fashion itself into a health care services and solutions company, rather than pure device firm. TYRX makes anti-bacterial envelopes for implanted devices, and has FDA clearances with cardiac implantable electronic devices and spinal cord neurostimulators.

You may also be interested in...

Medtronic Picks Up Surgical Safety Firm In $235 Million Deal

The device giant is buying RF Surgical Systems, which makes a radiofrequency-based technology to help prevent surgical sponges from being retained in a patient after a procedure. Sponge retention is a non-reimbursable "never event" under Medicare, driving hospital interest in solutions to reduce the occurrence.

Medtronic Puts Its 2014 Tyrx Buy To The Test With Large Study

The 7,000-patient WRAP-IT study will measure the clinical and cost benefits of employing the Tyrx antibacterial envelope, acquired by Medtronic last year, to reduce infections following cardiac rhythm management device implant procedures. Medtronic hopes to leverage new incentives for hospitals to cut infection rates.

Medtronic’s TYRX Antibacterial Implant Covering Launches In Europe

The company says its envelope used to cover cardiac devices during surgery has proven to be highly effective in reducing infections based on a study of over 1,000 patients in the U.S.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts